Xenetic Biosciences Toekomstige groei

Future criteriumcontroles 2/6

De winst van Xenetic Biosciences zal naar verwachting dalen met 34.4% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 35.9% per jaar. De winst per aandeel zal naar verwachting groeien met 25.8% per jaar.

Belangrijke informatie

-34.4%

Groei van de winst

25.8%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	35.9%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	21 Nov 2024

Recente toekomstige groei-updates

Recent updates

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Dec 15

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Dec 01

Xenetic Biosciences reports Q2 results

Aug 12

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Aug 02

Xenetic inks clinical manufacturing contract with Catalent

Jul 07

Xenetic Biosciences reports Q3 results

Nov 13

Winst- en omzetgroeiprognoses

NasdaqCM:XBIO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	2	-15	N/A	N/A	1
12/31/2025	2	-9	N/A	N/A	1
12/31/2024	2	-6	N/A	N/A	1
9/30/2024	3	-4	-3	-3	N/A
6/30/2024	3	-5	-3	-3	N/A
3/31/2024	2	-4	-4	-4	N/A
12/31/2023	3	-4	-4	-4	N/A
9/30/2023	2	-4	-4	-4	N/A
6/30/2023	2	-4	-4	-4	N/A
3/31/2023	2	-6	-4	-4	N/A
12/31/2022	2	-7	-5	-5	N/A
9/30/2022	2	-7	-6	-5	N/A
6/30/2022	1	-7	-6	-5	N/A
3/31/2022	1	-6	-5	-5	N/A
12/31/2021	1	-6	-5	-5	N/A
9/30/2021	1	-5	-4	-4	N/A
6/30/2021	1	-11	-4	-4	N/A
3/31/2021	1	-11	-5	-5	N/A
12/31/2020	0	-11	-4	-4	N/A
9/30/2020	0	-11	-5	-5	N/A
6/30/2020	0	-14	-6	-6	N/A
3/31/2020	0	-14	-6	-6	N/A
12/31/2019	0	-18	-6	-6	N/A
9/30/2019	N/A	-19	-6	-6	N/A
6/30/2019	N/A	-10	-5	-5	N/A
3/31/2019	N/A	-11	-6	-6	N/A
12/31/2018	N/A	-7	-6	-6	N/A
9/30/2018	8	-1	-1	-1	N/A
6/30/2018	8	-2	N/A	-1	N/A
3/31/2018	8	-3	N/A	0	N/A
12/31/2017	8	-4	N/A	1	N/A
9/30/2017	3	-12	N/A	-8	N/A
6/30/2017	3	-13	N/A	-7	N/A
3/31/2017	3	-58	N/A	-7	N/A
12/31/2016	3	-58	N/A	-9	N/A
9/30/2016	N/A	-57	N/A	-5	N/A
6/30/2016	N/A	-60	N/A	-6	N/A
3/31/2016	N/A	-14	N/A	-5	N/A
12/31/2015	N/A	-13	N/A	-5	N/A
9/30/2015	N/A	-13	N/A	-7	N/A
6/30/2015	N/A	-11	N/A	-8	N/A
3/31/2015	N/A	-13	N/A	-11	N/A
12/31/2014	N/A	-14	N/A	-13	N/A
9/30/2014	N/A	-14	N/A	-12	N/A
6/30/2014	N/A	-13	N/A	-12	N/A
3/31/2014	1	-11	N/A	-9	N/A
12/31/2013	1	-9	N/A	-6	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat XBIO de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat XBIO de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat XBIO de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van XBIO ( 35.9% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van XBIO ( 35.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van XBIO naar verwachting over 3 jaar hoog zal zijn

Xenetic Biosciences Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased to US$4.00

Consensus forecasts updated

Consensus EPS estimates increase to -US$0.55

Price target increased to US$5.00

Recent updates

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting Potential of Co-Administration of DNase I with CAR T Cells in Murine Model of Melanoma Lung Metastasis

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Xenetic Biosciences, Inc. Announces the Presentation of Positive Preclinical Data

Xenetic Biosciences, Inc., Annual General Meeting, Dec 11, 2024

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Xenetic Biosciences, Inc. Announces the Appointment of James Parslow as Interim Chief Executive Officer

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CLS Therapeutics Discloses its Views on Xenetic Biosciences

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform

Xenetic Biosciences, Inc., Annual General Meeting, Dec 06, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Xenetic Biosciences, Inc., Annual General Meeting, Dec 21, 2022

Xenetic Biosciences Receives a Non-Compliance Letter from Nasdaq

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board

Price target increased to US$4.00

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xenetic Biosciences, Inc., Annual General Meeting, Dec 07, 2022

Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, Inc.

Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Xenetic Biosciences reports Q2 results

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Xenetic inks clinical manufacturing contract with Catalent

Xenetic Biosciences Receives Written Notification from the Listing Qualifications Department of the Nasdaq

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Xenetic Biosciences, Inc. announced that it has received $0.86625 million in funding

High number of new directors

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$1.20 loss in 3Q 2020)

Consensus EPS estimates increase to -US$0.55

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.15 loss in 2Q 2020)

Price target increased to US$5.00

Xenetic Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

Xenetic Biosciences reports Q3 results

Xenetic Biosciences Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven